0.00Open0.00Pre Close0 Volume0 Open Interest13.00Strike Price0.00Turnover163.33%IV-45.25%PremiumOct 18, 2024Expiry Date4.05Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7944Delta0.0870Gamma2.06Leverage Ratio-0.0239Theta-0.0047Rho-1.63Eff Leverage0.0058Vega
Grifols Stock Discussion
FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients
Welcome to the end of the dog days of summer for a while; my name is Kevin Travers, and here are stories from the moomoo herd on Wall Street today.
$Intel (INTC.US)$ traded higher after the firm said it had bypassed Vietnam for a $3.3B project and in...
2. $Inspire Veterinary Partners (IVP.US)$
3. $Dynatronics (DYNT.US)$
4. $Zapp Electric Vehicles (ZAPP.US)$
5. $Maxeon Solar Technologies (MAXN.US)$
6. $Grifols (GRFS.US)$
7. $SinglePoint (SING.US)$
8. $Venus Concept (VERO.US)$
9. $IDEAYA Biosciences (IDYA.US)$
10. $Kuke Music (KUKE.US)$
- Reuters
Benzinga· 1 min ago
Grifols (GRF.MC) said Monday that the sale of its 20% stake in blood products company Shanghai RAAS to Chinese home appliance company Haier Group is expected to be completed by June.
The Spanish pharmaceutical company said both the buyer and seller secured the necessary domestic and overseas government approvals for the deal. It noted that the transaction still requires a compliance confirmation from the Shenzhen Stock Exchange.
No comment yet